Clinical Trial Update: Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma [EARLY_Phase 1]

View source ↗

Summary

Early-phase study evaluating CBL0137 in combination with ipilimumab and nivolumab for locally advanced or metastatic melanoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CBL0137 (CBL0137)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Locally Advanced or Metastatic Melanoma | EARLY_Phase 1 | Status: RECRUITING